Alimera Sciences Stock News

Although it's not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising, investors need to start preparing for t

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences, Inc. (NASDAQ:ALIM ) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Execut

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the

Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.

Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.

ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observ

Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

Positive findings from the RIVER study and data on retreatment with ILUVIEN available Positive findings from the RIVER study and data on retreatment with ILUVIEN available

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock